ODN 1982

Cat. No.:	HY-150729
CAS No.:	207623-15-2
Molecular Weight:	6364.1
Sequence:	DNA, d(P-thio)(T-C-C-A-G-G-A-C-T-T-C-T-C-T-C-A-G-G-T-T)
Target:	Others
Pathway:	Others
Storage:	-20°C, sealed storage, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

DNA, d(P-thio)(T-C-C-A-G-G-A-C-T-T-C-T-C-T-C-A-G-G-T-T)

SOLVENT & SOLUBILITY

In Vitro

H_2O : ≥ 20 mg/mL (3.14 mM)

* "≥" means soluble, but saturation unknown.

Preparing Stock Solutions

Solvent / Mass / Concentration	1 mg	5 mg	10 mg
1 mM	0.1571 mL	0.7857 mL	1.5713 mL
5 mM	---	---	---
10 mM	---	---	---

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

ODN 1982 is a unmethylated oligodeoxyribonucleotide (ODN) with no CpG motif, can be used to prepare DNA vaccines. ODN 1982 inhibits R-848 signaling. ODN 1982 sequence: 5'-tccaggacttctctcaggtt-3'[1][2].

In Vitro

ODN 1982 (0.1, 1 and 5 μM) has no influence on NF-κB induction in hTLR7-expressing HEK293 cells[2].

ODN 1982 (0.1-10 μM; 24 h) together with Loxoribine does not induce IL-12p40 above the medium background, and yields few TNF^+ monocytes[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Tudor D, et al. TLR9 pathway is involved in adjuvant effects of plasmid DNA-based vaccines. Vaccine. 2005 Jan 26;23(10):1258-64.

[2]. Jurk M, et al. Modulating responsiveness of human TLR7 and 8 to small molecule ligands with T-rich phosphorothiate oligodeoxynucleotides. Eur J Immunol. 2006 Jul;36(7):1815-26.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA